A new FDA regulatory pathway could accelerate approval of psychedelic therapies for resistant depression and PTSD, and experts speculate that psilocybin from Compass Pathways may be the first.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/race-first-psychedelic-approval-whos-leading-2026a1000e0n?src=rss
Author :
Publish date : 2026-05-01 19:42:00
Copyright for syndicated content belongs to the linked Source.
